AzitraAZTR
About: Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
Employees: 12
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
45% more capital invested
Capital invested by funds: $74.9K [Q3] → $109K (+$34.1K) [Q4]
43% more funds holding
Funds holding: 7 [Q3] → 10 (+3) [Q4]
1.56% more ownership
Funds ownership: 1.8% [Q3] → 3.35% (+1.56%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for AZTR.
Financial journalist opinion
